A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Conditions
- Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular Carcinoma
- Interventions
- Registration Number
- NCT03782207
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
- Detailed Description
The study will be split into separate cohorts based on the approved indications for atezolizumab treatment, excluding cisplatin ineligible participants receiving atezolizumab as first line of therapy (LOT1) for locally advanced/metastatic urothelial cancer (locally advanced/metastatic UC). The study may be amended for inclusion of new cohorts as these are approved in the participating countries. Participants will be included into each cohort based on their indication for receiving atezolizumab.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 2756
- Patient must have one of the following confirmed diagnoses for which atezolizumab is locally approved in the SmPC: (1) As monotherapy for the treatment of adult patients with locally advanced/metastatic UC after prior platinum-containing chemotherapy (Cohort 1 LOT2+mUC) or (2) As monotherapy for the treatment of adult patients with locally advanced/metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab (Cohort 2 LOT2+NSCLC) or (3) In combination with bevacizumab, paclitaxel and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC. Patients with EGFR activating mutations or ALK- positive tumour mutations should also have received targeted therapy (Cohort 3 LOT1 NSCLC) or (4) In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (Cohort 4 LOT1 ES-SCLC) or (5) As a monotherapy, for the treatment of metastatic NSCLC with high PD-L1 expression, previously untreated (Cohort 5 LOT1 NSCLC) or (6) In combination with bevacizumab for unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy (Cohort 6 LOT1 HCC) .
- Patient is administered atezolizumab therapy for the first time.
- Decision to administer atezolizumab must be made and documented prior to inclusion into the study and must follow local clinical practice.
- Patients not receiving treatment for a disease with atezolizumab according to standard of care and in line with the current summary of product characteristics (SPC) or local labelling. Cisplatin ineligible patients receiving atezolizumab LOT1 for the treatment of locally advanced/metastatic UC patients will be excluded
- Concomitant anti-cancer therapy at the time of starting atezolizumab on the index date not part of locally approved combination therapy with atezolizumab.
- Treatment with atezolizumab as part of a clinical trial or for compassionate use as part of a pre-approval or compassionate use program.
- Patients not receiving atezolizumab, but a biosimilar or non-original biologic.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort 5 (NSCLC LOT1) Atezolizumab Participants diagnosed with metastatic Non-Small Cell Lung cancer with high PD-L1 expression, previously untreated. Cohort 4 (ES-SCLC LOT1) Atezolizumab Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated. Enrollment is closed. Cohort 1 (UC LOT2+later lines[LOT2+] & platinum eligible LOT1) Atezolizumab Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy. Enrollment is closed. Cohort 2 (NSCLC LOT2 plus later lines [LOT2+]) Atezolizumab Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy. Enrollment closed. Cohort 3 (NSCLC LOT1 plus EGFR+/ALK+ LOT2+) Atezolizumab EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy. FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. Enrollment is closed. Cohort 6 (HCC LOT1) Atezolizumab Participants diagnosed with unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
- Primary Outcome Measures
Name Time Method OS at 2 Years After index date up to 2 years Percentage of participants alive 2 years after initiation of atezolizumab treatment.
Overall Survival (OS) Index date up to approximately 6 years Time from index date until date of death from any cause. Index date is the date of administration of the first ever dose of atezolizumab for each patient.
- Secondary Outcome Measures
Name Time Method Duration of Response (DoR) Index date up to approximately 6 years Time from first documentation of CR or PR (whichever occurs first) after index until death or PD.
Time to Loss of Clinical Benefit (TTLCB) Index date up to approximately 6 years Time from the index date to loss of clinical benefit as assessed by the treating physician.
Progression Free Survival (PFS) Index date up to approximately 6 years Time from index date to death or disease progression (PD).
Objective Response Rate (ORR) After index date up to approximately 6 years Percentage of participants who have a best overall response (BOR) of Complete Response (CR) or Partial Response (PR). BOR for each participant is the best response achieved after the index date prior to initiation of any subsequent treatment.
Time to Response Index date up to approximately 6 years Time from index date to first objective tumor response, CR or PR.
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Score Index date or after ICF signature, & approx. at 6, 12, and 24 weeks of treatment; then at approx. 3 months, 6 months, 12 months, & every 12 months thereafter until end of study (study planned duration up to approximately 6 years) EQ-5D-5L during and after atezolizumab treatment will be used to assess HRQoL. Scale is from 1-5 (no problems, slight problems, moderate problems, severe problems and extreme problems).
Total Number of Infusions of Atezolizuamb Treatment period until discontinuation (up to approximately 6 years) Duration of Treatment With Atezolizumab Index date until date of treatment discontinuation (up to approximately 6 years) Time to initiation of the first subsequent cancer-related therapy Up to approximately 6 years Number of Lines of Prior and Subsequent Cancer-Related Therapies Up to approximately 6 years Disease Control Rate (DCR) From 12 weeks after index date up to approximately 6 years Percentage of participants who have achieved CR, PR and stable disease at least 12 weeks after the index date.
Duration of DCR After index date up to approximately 6 years Time from first documentation of CR, PR or stable disease (whichever occurs first) after index until death or PD.
Number of Participants at Each Level of Karnofsky or ECOG Performance Status At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient. Number of Paricipants with Disease Stage TNM and IUCC At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient.) Percentage of Participants with Adverse Events Up to approximately 6 years
Trial Locations
- Locations (256)
Multiprofile Hospital for Active Treatment Uni Hospital
🇧🇬Panagyurishte, Bulgaria
Umhat Dr Georgi Stranski
🇧🇬Pleven, Bulgaria
University Hospital Palmed
🇧🇬Plovdiv, Bulgaria
Complex Oncological Center - Plovdiv, EOOD
🇧🇬Plovdiv, Bulgaria
DDODIU-Plovdiv, EOOD
🇧🇬Plovdiv, Bulgaria
Complex Oncological Center-Ruse EOOD
🇧🇬Ruse, Bulgaria
Tokuda Hospital
🇧🇬Sofia, Bulgaria
MHAT SofiaMed
🇧🇬Sofia, Bulgaria
Fundacion Clinica Valle del Lili
🇨🇴Cali, Colombia
Klinicki Bolnicki Centar Split
🇭🇷Split, Croatia
International Medical Center
🇪🇬Cairo, Egypt
North Estonia Medical Centre Foundation
🇪🇪Tallinn, Estonia
Tartu Uni Hospital
🇪🇪Tartu, Estonia
Clinique Du Docteur Calabet
🇫🇷Agen, France
Ch Du Pays D Aix
🇫🇷Aix En Provence, France
Clinique de l'Europe
🇫🇷Amiens, France
Centre Hospitalier Uni Ire
🇫🇷Angers, France
Hopital Prive D Antony
🇫🇷Antony, France
Hopital Jean Minjoz
🇫🇷Besancon, France
Ch De Beziers
🇫🇷Beziers, France
Clinique Tivoli
🇫🇷Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine
🇫🇷Bordeaux, France
Hopital Cote De Nacre
🇫🇷Caen, France
Ch De Chambery
🇫🇷Chambery, France
Oncologie 37
🇫🇷Chambray Les Tours, France
Hopital Gabriel Montpied
🇫🇷Clermont-ferrand, France
Ch De Compiegne
🇫🇷Compiegne, France
Ch Laennec
🇫🇷Creil, France
Centre Georges Francois Leclerc
🇫🇷Dijon, France
Hopital Simone Veil Eaubonne
🇫🇷Eaubonne, France
Chi Alpes Du Sud Site De Gap
🇫🇷GAP, France
Hopital Nord Ouest
🇫🇷Gleize, France
Ch Saint Louis
🇫🇷La Rochelle, France
Hopital La Source
🇫🇷La Source, France
Hopital Louis Pasteur
🇫🇷Le Coudray, France
Centre Hospitalier Du Mans
🇫🇷Le Mans, France
Hôpital Privé La Louviere
🇫🇷Lille, France
Hopital Dupuytren
🇫🇷Limoges, France
Ch Bretagne Sud Site Scorff
🇫🇷Lorient, France
Hopital Privé Jean Mermoz
🇫🇷Lyon, France
Clinique Clementville
🇫🇷Montpellier, France
Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque
🇫🇷Montpellier, France
Hopital Emile Muller
🇫🇷Mulhouse, France
Arkhangelsk Regional Clinical Oncology Dispensary
🇷🇺Arkhangelsk, Arhangelsk, Russian Federation
Semmelweis Egyetem, AOK, Pulmonologiai Klinika
🇭🇺Budapest, Hungary
Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika
🇭🇺Debrecen, Hungary
HCG Cancer Center
🇮🇳Ahmedabad, Gujarat, India
Sunshine Global Hospital (A unit of Baroda Medicare Pvt Ltd)
🇮🇳Surat CITY, Gujarat, India
Manipal Hospital
🇮🇳Bangalore, Karnataka, India
Aster Medcity
🇮🇳Kochi, Kerala, India
MVR Cancer Centre and Research Institute
🇮🇳Kozhikode, Kerala, India
MOC Cancer Care & Research Centre
🇮🇳Mumbai, Maharashtra, India
AIG Hospitals
🇮🇳Gachibowli, Telangana, India
Ospedale San Salvatore, UOC Oncologia
🇮🇹L?Aquila, Abruzzo, Italy
Kuwait Cancer control center
🇰🇼Shuwakh Industrial, Kuwait
Middle East Institute of Health Hospital
🇱🇧Bsalim, Mount Lebanon-Metn, Lebanon
Hospital of Lithuanian University of Health Sciences Kaunas Clinics Public Institution
🇱🇹Kaunas, Lithuania
Medica sur Hospital
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Clinica Opcion Oncologia S.A. de C.V.
🇲🇽Monterrey, Nuevo LEON, Mexico
Oncare
🇲🇽San Pedro Garza García, Nuevo LEON, Mexico
Onze Lieve Vrouwe Gasthuis, locatie Oost
🇳🇱Amsterdam, Netherlands
Catharina ziekenhuis
🇳🇱Eindhoven, Netherlands
Medisch Centrum Leeuwarden
🇳🇱Leeuwarden, Netherlands
Zaans Medisch Centrum
🇳🇱Zaandam, Netherlands
Sultan Qaboos Comprehensive Cancer Care & Research Center
🇴🇲Muscat, Oman
Wojewódzki Szpital Specjalistyczny im. M. Kopernika w ?odzi
🇵🇱?ód?, Poland
Instytut Gruzlicy i Chorob P?uc
🇵🇱Warszawa, Poland
Institutul Clinic Fundeni Bucuresti
🇷🇴Bucharest, Romania
Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor
🇷🇴Cluj-Napoca, Romania
AZ Delta (Campus Rumbeke)
🇧🇪Roeselare, Belgium
Complex Oncology Center Burgas
🇧🇬Burgas, Bulgaria
Centrum Pulmonologii i Torakochirurgii
🇵🇱Bystra, Poland
Wojewodzki Szpital Zespolony
🇵🇱Elblag, Poland
Regionalny Szpital Specjalistyczny im. W. Bieganskiego
🇵🇱Grudzi?dz, Poland
The York Hospital
🇬🇧York, United Kingdom
AZ KLINA
🇧🇪Brasschaat, Belgium
AZ Damiaan
🇧🇪Oostende, Belgium
Hospital Universitario Austral
🇦🇷Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Klinikum Klagenfurt
🇦🇹Klagenfurt, Austria
Landesklinikum Krems
🇦🇹Krems, Austria
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
Hopital Caremeau
🇫🇷Nimes, France
Polyclinique Kenval
🇫🇷Nimes, France
Institut Curie
🇫🇷Paris, France
Hopital Cochin
🇫🇷Paris, France
Hopital Europeen Georges Pompidou
🇫🇷Paris, France
Centre Hospitalier
🇫🇷PAU, France
Centre Catalan D' Oncologie
🇫🇷Perpignan, France
Ch Annecy - Genevois
🇫🇷Pringy, France
Hopital De La Maison Blanche
🇫🇷Reims, France
Clinique Mutualiste L Estuaire
🇫🇷Saint Nazaire, France
Hopital Nord
🇫🇷Saint Priest En Jarez, France
Hopital Robert Pax
🇫🇷Sarreguemines, France
Ch De Saint Quentin
🇫🇷St Quentin, France
Hopital Sainte Musse
🇫🇷Toulon, France
Hopital Larrey
🇫🇷Toulouse, France
Centre Hospitalier de Valence
🇫🇷Valence, France
Ch Bretagne Atlantique
🇫🇷Vannes, France
Hopital Robert Schuman
🇫🇷Vantoux, France
University of Pecs
🇭🇺Pecs, Hungary
Református Pulmonológiai Centrum
🇭🇺Törökbálint, Hungary
Grande Ospedale Metropolitano
🇮🇹Reggio Calabria, Calabria, Italy
Az. Osp. Monaldi
🇮🇹Napoli, Campania, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Campania, Italy
A.O. Universitaria Policlinico Di Modena
🇮🇹Modena, Emilia-Romagna, Italy
Azienda Ospedaliera San Camillo Forlanini
🇮🇹Roma, Lazio, Italy
Ospedale S.S. Trinità Nuovo
🇮🇹Sora, Lazio, Italy
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
🇵🇱Bydgoszcz, Poland
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST)
🇮🇹Genova, Liguria, Italy
Ospedale Maggiore Policlinico
🇮🇹Milano, Lombardia, Italy
Asst Santi Paolo E Carlo
🇮🇹Milano, Lombardia, Italy
Asst Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Lombardia, Italy
Ospedale Di Circolo E Fondazione Macchi
🇮🇹Varese, Lombardia, Italy
Ospedale Di Macerata
🇮🇹Macerata, Marche, Italy
Ospedale Civile SS. Antonio E Biagio DI Alessandria
🇮🇹Alessandria, Piemonte, Italy
Ospedale Oncologico A.Businco
🇮🇹Cagliari, Sardegna, Italy
Azienda Ospedaliero Universitaria Di Sassari
🇮🇹Sassari, Sardegna, Italy
Az Ospedaliera Nuovo Garibaldi Quartiere Nesima
🇮🇹Catania, Sicilia, Italy
Az. Osp. Uni. Ria Policlinico G. Martino
🇮🇹Messina, Sicilia, Italy
Azienda Ospedaliero Universitaria Careggi
🇮🇹Firenze, Toscana, Italy
Azienda Ospedaliero-Universitaria Careggi
🇮🇹Firenze, Toscana, Italy
Ospedale Nuovo Della Versilia
🇮🇹Lido Di Camaiore, Toscana, Italy
A.O.U. Integrata Verona - Policlinico G.B. Rossi
🇮🇹Verona, Veneto, Italy
Saint George Hospital
🇱🇧Beirut, Lebanon
National Cancer Institute
🇱🇹Vilnius, Lithuania
Royal Hospital
🇴🇲Muscat, Oman
Azienda ULSS 8 Berica
🇮🇹Vicenza, Veneto, Italy
Shaukat Khanum Memorial Cancer Hospital
🇵🇰Lahore, Punjab (province), Pakistan
Aga Khan University
🇵🇰Karachi, Sindh (province), Pakistan
WZZOZ Centrum Leczenia Chorob Pluc i Rehabilitacji
🇵🇱?ód?, Poland
Beskidzkie Centrum Onkologii - Szpital Miejski im. Jana Pawla II
🇵🇱Bielsko-Bia?a, Poland
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
🇵🇱Lublin, Poland
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
🇵🇱Olsztyn, Poland
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
🇵🇱Otwock, Poland
Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu
🇵🇱Pozna?, Poland
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
🇵🇱Warszawa, Poland
Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii
🇵🇱Wroc?aw, Poland
Hospital Geral
🇵🇹Coimbra, Portugal
Centro Clinico Champalimaud
🇵🇹Lisboa, Portugal
Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Hospital Pedro Hispano
🇵🇹Matosinhos, Portugal
Centro Hospitalar do Porto ? Hospital de Santo António
🇵🇹Porto, Portugal
Hospital CUF Porto
🇵🇹Porto, Portugal
CHVNG/E_Unidade 1
🇵🇹Vila Nova De Gaia, Portugal
Altai Regional Oncological Center
🇷🇺Barnaul, Altaj, Russian Federation
Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky
🇷🇺Krasnoyarsk, Krasnodar, Russian Federation
Tan Tock Seng Hospital
🇸🇬Singapore, Singapore
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
University Medical Center Ljubljana
🇸🇮Ljubljana, Slovenia
Univerzitetni klini?ni center Maribor
🇸🇮Maribor, Slovenia
Complejo Hospitalario Torrecardenas
🇪🇸Almería, Almeria, Spain
Hospital General de Mataro
🇪🇸Mataro, Barcelona, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Hospital Universitario Son Espases
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
🇪🇸Santiago de Compostela, LA Coruna, Spain
Hospital Infanta Sofia
🇪🇸San Sebastian de Los Reyes, Madrid, Spain
Clinica Universitaria de Navarra
🇪🇸Pamplona, Navarra, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario de Canarias
🇪🇸La Laguna, Tenerife, Spain
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
Complejo Hospitalario Nuestra Señora de la Candelaria
🇪🇸Santa Cruz de Tenerife, Tenerife, Spain
Hospital Universitario Infanta Cristina
🇪🇸Badajoz, Spain
Hospital Universitari Dexeus - Grupo Quironsalud
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Complejo Asistencial Universitario De Burgos
🇪🇸Burgos, Spain
Hospital San Pedro De Alcantara
🇪🇸Caceres, Spain
Hospital Clinico de Granada
🇪🇸Granada, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
🇪🇸Jaen, Spain
Complejo Asistencial Universitario de Leon
🇪🇸Leon, Spain
Hospital Lucus Augusti
🇪🇸Lugo, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal
🇪🇸Madrid, Spain
Hospital Universitario Puerta de Hierro
🇪🇸Madrid, Spain
Hospital Quiron de Madrid
🇪🇸Madrid, Spain
Complejo Hospitalario de Orense
🇪🇸Orense, Spain
Hospital General de Segovia
🇪🇸Segovia, Spain
Hospital Univ. Nuestra Señora de Valme
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valladolid
🇪🇸Valladolid, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Barnet Hospital
🇬🇧Barnet, United Kingdom
Royal United Hospital
🇬🇧Bath, United Kingdom
Heartlands Hospital
🇬🇧Birmingham, United Kingdom
Castle Hill Hospital
🇬🇧Cottingham, United Kingdom
Huddersfield Royal Infirmary
🇬🇧Huddersfield, United Kingdom
Airedale General Hospital
🇬🇧Keighley, United Kingdom
St James Hospital
🇬🇧Leeds, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
St George's Hospital
🇬🇧London, United Kingdom
Hammersmith Hospital
🇬🇧London, United Kingdom
Maidstone Hospital
🇬🇧Maidstone, United Kingdom
Torbay Hospital
🇬🇧Torquay, United Kingdom
Consultorio Privado Korbenfeld
🇦🇷Caba, Argentina
Lucen S.A.
🇦🇷Ciudad Autónoma de Buenos Aires, Argentina
Sanatorio Allende
🇦🇷Cordoba, Argentina
Sanatorio de la Mujer
🇦🇷Rosario, Argentina
Fundacion Koriza
🇦🇷Santa Rosa, Argentina
Salzkammergut-Klinikum Voecklabruck
🇦🇹Vöcklabruck, Austria
AZ St Maarten Campus Leopoldstr
🇧🇪Mechelen, Belgium
CHU UCL Mont-Godinne
🇧🇪Mont-godinne, Belgium
Sint Trudo Ziekenhuis
🇧🇪Sint-Truiden, Belgium
Beneficencia Portuguesa de Sao Paulo
🇧🇷Sao Paulo, São Paulo, Brazil
Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
🇧🇬Plovdiv, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
🇧🇬Sofia, Bulgaria
MBAL Serdika EOOD
🇧🇬Sofia, Bulgaria
Specialized Hospital for Active Cancer Treatment, Dr. Mark Antonov Markov - Varna Ltd
🇧🇬Varna, Bulgaria
Centro de Estudios Clínicos SAGA
🇨🇱Santiago, Chile
Angiografia del Occidente
🇨🇴Cali, Colombia
Hospital Pablo Tobon Uribe
🇨🇴Medellin, Colombia
Clinica ASTORGA
🇨🇴Medellin, Colombia
Clinical Hospital Centre Osijek
🇭🇷Osijek, Croatia
Clinical Hospital Center Sestre Milosrdnice
🇭🇷Zagreb, Croatia
Clinical Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
SUN Oncology center- Alexandria
🇪🇬Alexandria, Egypt
Yasser Abdel Kader Private Clinic
🇪🇬Cairo, Egypt
Air Force Specialized Hospital
🇪🇬Cairo, Egypt
Barsoum Oncology Center
🇪🇬Cairo, Egypt
Cairo Oncology Center
🇪🇬Cairo, Egypt
CHG Henri Dufaut médecine interne-onco-hematologie
🇫🇷Avignon, France
CH de Beauvais
🇫🇷Beauvais, France
Hopital Europeen
🇫🇷Marseille, France
Service de pneumologie Clinique médico-chirurgicale Tessier
🇫🇷Valenciennes Cedex, France
Orszagos Koranyi TBC es Pulmonologiai Intezet
🇭🇺Budapest, Hungary
Bashkirian Republican Clinical Oncology Dispensary
🇷🇺UFA, Baskortostan, Russian Federation
FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
🇷🇺Saint-Petersburg, Sankt Petersburg, Russian Federation
Medical Clinic "AB Medical group"
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
EuroCityClinic
🇷🇺Sankt-peterburg, Sankt Petersburg, Russian Federation
Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic
🇷🇺Kazan, Tatarstan, Russian Federation
SBIH Kaluga Region Clinical Oncology Dispensary
🇷🇺Kaluga, Russian Federation
Tver Regional Oncology Clinical Dispensary
🇷🇺Tver, Russian Federation
Tawam Hospital
🇦🇪Al Ain, United Arab Emirates
Clatterbridge Cancer Centre
🇬🇧Bebington, United Kingdom
Queen Elizabeth Hospital
🇬🇧London, United Kingdom
East Lancashire Hospitals NHS Trust
🇬🇧Burnley, United Kingdom
Addenbrookes Hospital
🇬🇧Cambridge, United Kingdom
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
Royal Surrey County Hospital
🇬🇧Guildford, United Kingdom
Northwick Park Hospital
🇬🇧Harrow, United Kingdom
Royal Marsden Hospital
🇬🇧Kingston upon Thames, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
Guys and St Thomas Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - Fulham
🇬🇧London, United Kingdom
Charing Cross Hospital
🇬🇧London, United Kingdom
The Christie
🇬🇧Manchester, United Kingdom
James Cook Hospital
🇬🇧Middlesbrough, United Kingdom
Freeman Hospital
🇬🇧Newcastle upon Tyne, United Kingdom
Churchill Hospital
🇬🇧Oxford, United Kingdom
Royal Preston Hospital
🇬🇧Preston, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, United Kingdom
Royal Stoke University Hospital
🇬🇧Stoke on Trent, United Kingdom
Royal Marsden Hospital (Sutton)
🇬🇧Sutton, United Kingdom
Royal Cornwall Hospital
🇬🇧Truro, United Kingdom
Pinderfields General Hospital
🇬🇧Wakefield, United Kingdom
Great Western Hospitals NHS Foundation Trust.
🇬🇧Wiltshire, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom